Theravance Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Supplementary Financial Data (unaudited)
SUPPLEMENTARY FINANCIAL DATA
(UNAUDITED)
(In thousands, except per share data)
The following table presents certain unaudited consolidated quarterly financial information for the eight quarters in the periods ended December 31, 2023 and 2022. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein. For all periods prior to the quarter ended September 30, 2022, the information below has been retroactively adjusted for discontinued operations presentation.
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · For the Quarter Ended | ||||||||||||
| · March 31, · June 30, · September 30, · December 31, | ||||||||||||
| 2023 | | | | | | | | | | | | |
| Total revenue | | $10,417 | | $13,749 | | $15,693 | | $17,565 | ||||
| Costs and expenses | | 35,329 | | 29,872 | | 24,453 | | 23,805 | ||||
| Loss from operations | | (24,912) | | (16,123) | | (8,760) | | (6,240) | ||||
| Net loss from continuing operations | | | (22,088) | | | (15,645) | | | (8,950) | | | (8,510) |
| Net income from discontinued operations | | | — | | | — | | | — | | | — |
| Net income (loss) | | (22,088) | | (15,645) | | (8,950) | | (8,510) | ||||
| Net loss from continuing operations - basic and diluted per share | | | (0.35) | | | (0.28) | | | (0.17) | | | (0.17) |
| Net income from discontinued operations - basis and diluted per share | | | — | | | — | | | — | | | - |
| Net income (loss) - basis and diluted per share | | $(0.35) | | $(0.28) | | $(0.17) | | $(0.17) | ||||
| | | | | | | | | | | | | |
| 2022 | | | | | | | | | | | | |
| Total revenue | | $13,196 | | $11,050 | | $12,451 | | $14,649 | ||||
| Costs and expenses | | 51,698 | | 37,929 | | 21,595 | | 32,081 | ||||
| Loss from operations | | (38,502) | | (26,879) | | (9,144) | | (17,432) | ||||
| Net loss from continuing operations | | | (41,538) | | | (26,570) | | | (10,460) | | | (14,256) |
| Net income from discontinued operations | | | 15,592 | | | 18,379 | | | 927,091 | | | 3,894 |
| Net income (loss) | | (25,946) | | (8,191) | | 916,631 | | (10,362) | ||||
| Net loss from continuing operations - basic and diluted per share | | | (0.55) | | | (0.35) | | | (0.21) | | | (0.21) |
| Net income from discontinued operations - basis and diluted per share | | | 0.21 | | | 0.24 | | | 12.35 | | | 0.06 |
| Net income (loss) - basis and diluted per share | | $(0.34) | | | (0.11) | | | 12.14 | | | (0.15) | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Share of Total YUPELRI Net Sales (1) | | | | | | | | | | | | |
| | | For the Quarter Ended | ||||||||||
| | | March 31, | June 30, | September 30, | December 31, | |||||||
| 2023 | | $16,434 | | $19,263 | | $20,414 | | $21,225 | ||||
| 2022 | | $15,283 | | $17,177 | | $18,698 | | $19,495 | ||||
| (1) | The Company co-promotes YUPELRI in the US under a profit and loss sharing arrangement with Viatris (65% to Viatris; 35% to Theravance Biopharma). The amounts represent the Company’s implied 35% share of the total net sales of YUPELRI that were recognized within Viatris’ financial statements for the periods presented. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.